Eli Lilly to invest $750M in US drug production

Eli Lilly, in collaboration with contract manufacturing company Resilience, announced a $750 million investment to expand its drug manufacturing capabilities within the United States. This investment aims to increase biopharmaceutical production and strengthen the local supply chain, while creating 400 highly skilled jobs in Cincinnati, Ohio. The expansion is part of the company's efforts to meet the growing demand for its medications, especially as the partnership between the two companies began in 2023 and has already resulted in the production of over 150 million doses for patients in the U.S. This investment is part of Eli Lilly's broader plan to boost its investments in the American market, which have exceeded $55 billion since 2020, in line with the U.S. government’s initiatives to promote domestic pharmaceutical manufacturing.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل